ОЦЕНКА КЛИНИЧЕСКОЙ ЗНАЧИМОСТИ СХЕМЫ ЛЕЧЕНИЯ ИФОСФАМИДОМ И ЦИСПЛАТИНОМ ПРИ РЕЦИДИВНОМ ОСТЕОСАРКОМЫ
Keywords:
Ключевые слова: Остеосаркома, химиотерапия, метастаз остеосаркома, рецедивAbstract
Аннотация. При сравнение трех групп (IPE, IPA и удаление метастазы после адьювантной ПХТ наблюдалось стабилизация у 6 больных из 12 при IPA (схема) и у 10 больных из 17 больных при IPE (cхема), что ожиданий эффективность в данных группах больных схем одинаковы. Общее 5-летнее выживаемость больных после хирургическом удаленного отдаленных метастазов составило 51.2%.
References
1. Angiolillo Krailo М., Laver J. et al. A comparison of TPO and rhlL-11 following iphosphamide (I), carboplatin (C) and etoposide (E) (ICE) in pediatric patients with recurrent solid tumors or lymphoma // Proc. ASCO.— 2004.™Abstr. 8535.
2. Bacci G., Longhi A., Cesari M. et al. F. Influence of local recurrence on survival in patients with extremity osteo¬sarcoma treated with non adjuvant chemotherapy // Cancer (Philad.).-2006.-Vol. 106.-P. 2701-2706.
3. Berrak S.G., Pearson М., Berbero lu S. et al. High- dose iphosphamide in relapsed pediatric osteosarcoma: therapeutic effects and renal toxicity // Pediatr. Blood. Cancer.-2005.-Vol. 44.-P. 215-219.
4. Bielack S., Kempf-Bielack B. Branscheid D. et.al. Relapsed osteosarcoma: an analysis of 576 coopera¬tive osteosarcoma study group (pOSS) patients // Proc. ASCO.-2003.-Abstr. 3305. I
5. Bielack S., Carrie D and Jost L. Osteosarcoma: ESMO Clinical Recommendations for d follow-up // Ann. Oncol.—2008 P. ii94-ii96.
6. Chou A.J., Merola PR., Wexler L.H. et al. Treatment of osteosarcoma at first recurrence after contemporary therapy : The Memorial Sloan-H experience // Cancer (Philad P. 2214-2221.
7. Crompton B.D., Golds by R.E Survival after recurrence of O! experience at a single institute Cancer.-2006.-Vol. 47.-P. 2
8. Divisi D., Gizzonio D., Crisci R. osteosarcoma lung metastases Surg.-2006.-Vol. 54.-P. 328'
9. Donfrancesco A., Jenkner A., line topotecan and high-dc followed by ICE in high-risk ASCO.—2004.—Abstr. 8536.
10. Ferrari S., Briccoli A., Mercut survival in osteosarcoma of the prognosis, treatment and -Vol. 19 (Suppl. 2).- ettering Cancer Center ).-2005.-Vol. 104.- Weinberg V.K. et al. osteosarcoma: a 20-year ion // Pediatr. Blood. 5-259. Multimodal treatment of // Thorac. Cardiovasc. 331. Oastellano I. et al. Front- se cyclophosphamide neuroblastoma // Proc. Hawkins D.S., Arndt C.A. Pattern of disease recurrence and prognostic factors in patients with osteosarcoma treated with contemporary chemotherapy // Cancer (Philad.).-2003.-Vol. 98.-P. 2447-2456
11. Jordan K., Kechel Т., Mueller L.P. et al. Feasibility of a combination of high dose chemotherapy iphosphamide, carboplatin, etoposide (ICE) plus stem and bevacizumab in refractory sarcoma and germ cell tumors // Proc. ASCO.-2005.-Abstr. 9070.
12. Kempy-Bielack B., Bielack S., Jurgens H. et al. Osteo¬sarcoma relapjse after combined modality therapy: an analysis of j unselected patients in the Cooperative Osteosarcoma Study Group (COSS) // J. Clin. Oncol.— 2005.-Vol. 23|-R 559-568.
13. Kudawara М., Aono K., Ohzono. et al. Efficacy of ifos¬famide, carboplatinum and etoposide (ICE) with or without paclitaxel in the second-line treatment of advanced or relapsed bone and soft tissue sarcomas // Proc. ASCO.—2005. f-Abstr. 9075.
14. Leu K.M., L.J., Shewach D. et al. Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma // J. Clin. Oncol.- 2004.—Vol. 22.-P. 1706-1712.
